Lipoprotein disorders and cardiovascular risk

被引:45
|
作者
Genest, J [1 ]
机构
[1] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Cardiol,Cardiovasc Genet Lab, Montreal, PQ H3A 1A1, Canada
关键词
D O I
10.1023/A:1024449603891
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Disorders of lipoproteins often lead to disease in humans. Most often the sequelae of long-term dyslipoproteinaemia lead to atherosclerotic vascular disease in all arterial beds. Plasma elevation of low-density lipoprotein cholesterol (LDL-C), very low-density lipoproteins ( VLDL) and lipoprotein( a), and reduced levels of high-density lipoproteins (HDL-C) are risk factors for coronary artery disease. Severe elevations of plasma triglycerides may lead to acute pancreatitis. In Western societies and in emerging economies, lifestyle contributes to the expression of lipoprotein disorders. Many dyslipoproteinaemias have a genetic aetiology. This review will examine the contribution of genetic lipoprotein disorders in human disease. Emphasis will be placed on monogenic disorders that are associated with coronary artery disease and novel causes of disorders of high-density lipoproteins. The consideration of screening and treatment of affected individuals, especially children, must take into account the severity of the phenotype, the long-term risk of developing vascular disease and available evidence of clinical benefit in a group of diseases that are mostly asymptomatic until manifestations of organ ischaemia in the heart, limbs or brain.
引用
收藏
页码:267 / 287
页数:21
相关论文
共 50 条
  • [41] Is lipoprotein(a) cholesterol a significant indicator of cardiovascular risk?
    Nauck, M
    März, W
    Wieland, H
    CLINICAL CHEMISTRY, 2000, 46 (03) : 436 - 437
  • [42] LIPOPROTEIN(A) AND CARDIOVASCULAR RISK IN HYPERTENSION: A RETROSPECTIVE STUDY
    Vythoulkas-Biotis, Nikolaos
    Kyvelou, Stela-Maria
    Lytra, Thekla
    Anastasiou, Theocharis
    Karpanou, Evanggelia
    Vyssoulis, Gregory
    JOURNAL OF HYPERTENSION, 2023, 41 : E101 - E101
  • [43] LIPOPROTEIN(A) IS ELEVATED IN PSORIASIS AND ASSOCIATED WITH CARDIOVASCULAR RISK
    Garshick, Michael Seth
    Drenkova, Kamelia
    Barrett, Tessa
    Schwartzbard, Arthur
    Weintraub, Howard
    Scher, Jose
    Fisher, Edward
    Berger, Jeffrey
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1580 - 1580
  • [44] Use of Emerging Lipoprotein Risk Factors in Assessment of Cardiovascular Risk
    Grundy, Scott M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (23): : 2540 - 2542
  • [45] AT-RISK: AuToimmune disorders and cardiovascular RISK
    Conrad, N.
    Verbeke, G.
    Molenberghs, G.
    Goetschalckx, L.
    Callender, T.
    Rahimi, K.
    Mason, J. C.
    McMurray, J. J. V.
    Verbakel, J. Y.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2862 - 2862
  • [46] LIPOPROTEIN(A) AND SMALL DENSE LOW DENSITY LIPOPROTEIN SUBFRACTIONS AS CARDIOVASCULAR RISK FACTORS
    Afanasieva, O.
    Utkina, E.
    Artemieva, N.
    Ezhov, M.
    Matchin, Y.
    Adamova, I.
    Pokrovsky, S.
    ATHEROSCLEROSIS, 2015, 241 (01) : E101 - E101
  • [47] Cardiovascular risk factors in bipolar disorders
    Andreassen, O. A.
    BIPOLAR DISORDERS, 2008, 10 : 5 - 5
  • [48] An Overview of Cardiovascular Risk in Pituitary Disorders
    Ntali, Georgia
    Markussis, Vyron
    Chrisoulidou, Alexandra
    MEDICINA-LITHUANIA, 2024, 60 (08):
  • [49] Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects
    Schmitz G.
    Orsó E.
    Clinical Research in Cardiology Supplements, 2015, 10 (Suppl 1) : 21 - 25
  • [50] LIPOPROTEIN (A) IS ELEVATED IN PSORIATIC DISEASE AND ASSOCIATED WITH CARDIOVASCULAR RISK
    Garshick, Michael Seth
    Drenkova, Kamelia
    Katz, Stuart
    Weber, Brittany
    Weintraub, Howard S.
    Schwartzbard, Arthur
    Haberman, Rebecca
    Fisher, Edward A.
    Neimann, Andrea
    Scher, Jose
    Berger, Jeffrey S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1561 - 1561